Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage ...

Over the last five years, Vertex's stock has displayed a trend of positive one-day returns in 58% of cases following earnings ...

Vertex Pharmaceuticals' non-opioid painkiller significantly decreased pain in patients with diabetes suffering from chronic nerve pain in a mid-stage trial, fueling efforts to develop a treatment ...

BOSTON (AP) — BOSTON (AP) — Vertex Pharmaceuticals Inc. (VRTX) on Monday reported second-quarter profit of $1.03 billion. The Boston-based company said it had net income of $3.99 per share. Earnings, ...

Vertex's pain trial hits endpoint but sinks stock as placebo comparison spooks investors By Nick Paul Taylor Dec 19, 2024 7:41am Vertex Pharmaceuticals pain drug clinical trial data Clinical Data ...

Vertex Pharmaceuticals on Monday reported disappointing first-quarter earnings impacted by weaker-than-expected sales of its drugs for cystic fibrosis, and little or no contributions from a gene ...

It may be the end of the road for VX-264, but Vertex still has another islet cell treatment in development in the form of zimislecel. This allogeneic human stem cell-derived islet cell therapy is ...

Vertex is faced with an access challenge as it is charging $15.50 for a 50 mg dose of Journavx, which works out to $420 for a two-week course. Generic opioids, meanwhile, go for roughly $0.50 a pill.

Vertex Pharmaceuticals is not making its drug, Trikafta, available in poorer countries, where thousands of diagnosed patients stand to benefit. Shwetha Sree, left, with her 5-year-old son Vihaan ...

Vertex Pharmaceuticals is stopping development of VX-264, an experimental cell therapy/medical device treatment for type 1 diabetes, after an early look at Phase 1/2 data fell short of efficacy goals.